TY - JOUR
T1 - Evaluation and Management of Patients With Stable Angina
T2 - Beyond the Ischemia Paradigm: JACC State-of-the-Art Review
AU - Ferraro, Richard
AU - Latina, Jacqueline M.
AU - Alfaddagh, Abdulhamied
AU - Michos, Erin D.
AU - Blaha, Michael J.
AU - Jones, Steven R.
AU - Sharma, Garima
AU - Trost, Jeffrey C.
AU - Boden, William E.
AU - Weintraub, William S.
AU - Lima, João A.C.
AU - Blumenthal, Roger S.
AU - Fuster, Valentin
AU - Arbab-Zadeh, Armin
N1 - Funding Information:
Dr. Blaha has received grant support from Amgen Foundation; and has been on the advisory board for Amgen, Sanofi, Regeneron, Novartis, Novo Nordisk, Bayer, Akcea, and Kowa. Dr. Arbab-Zadeh has received grant support from Canon Medical Systems. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2020 American College of Cardiology Foundation
PY - 2020/11/10
Y1 - 2020/11/10
N2 - Coronary heart disease is a chronic, systemic disease with a wide range of associated symptoms, clinical outcomes, and health care expenditure. Adverse events from coronary heart disease can be mitigated or avoided with lifestyle and risk factor modifications, and medical therapy. These measures are effective in slowing the progression of atherosclerotic disease and in reducing the risk of thrombosis in the setting of plaque disruptions. With increasing effectiveness of prevention and medical therapy, the role of coronary artery revascularization has decreased and is largely confined to subgroups of patients with unacceptable angina, severe left ventricular systolic dysfunction, or high-risk coronary anatomy. There is a compelling need to allocate resources appropriately to improve prevention. Herein, we review the scientific evidence in support of medical therapy and revascularization for the management of patients with stable coronary heart disease and discuss implications for the evaluation of patients with stable angina and public policy.
AB - Coronary heart disease is a chronic, systemic disease with a wide range of associated symptoms, clinical outcomes, and health care expenditure. Adverse events from coronary heart disease can be mitigated or avoided with lifestyle and risk factor modifications, and medical therapy. These measures are effective in slowing the progression of atherosclerotic disease and in reducing the risk of thrombosis in the setting of plaque disruptions. With increasing effectiveness of prevention and medical therapy, the role of coronary artery revascularization has decreased and is largely confined to subgroups of patients with unacceptable angina, severe left ventricular systolic dysfunction, or high-risk coronary anatomy. There is a compelling need to allocate resources appropriately to improve prevention. Herein, we review the scientific evidence in support of medical therapy and revascularization for the management of patients with stable coronary heart disease and discuss implications for the evaluation of patients with stable angina and public policy.
KW - atherosclerosis
KW - coronary artery disease
KW - coronary heart disease
KW - ischemic syndrome
KW - stable ischemic heart disease
UR - http://www.scopus.com/inward/record.url?scp=85094104582&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094104582&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2020.08.078
DO - 10.1016/j.jacc.2020.08.078
M3 - Review article
C2 - 33153586
AN - SCOPUS:85094104582
SN - 0735-1097
VL - 76
SP - 2252
EP - 2266
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 19
ER -